← Back to The Daily Signal
A CPAP machine with its breathing hose and face mask on a table

The standard treatment. One of the two trials kept CPAP running alongside the pill.

Mnalis

Illustrative. Not equipment from the trials.

Peptides

The GLP-1 Pill Cut Sleep Apnea Breathing Pauses by 12 to 13 an Hour More Than Placebo

Sleep apnea is one of the clearest places where weight and health meet: extra tissue around the airway makes it collapse at night, and the pauses in breathing that follow strain the heart. An injectable GLP-1 drug already has approval for this. The question these trials asked is whether a pill can do something similar.

Written by Sama Alabed · November 19, 2026

The short version

Two trials, two kinds of patients

The trials enrolled 712 adults with moderate to severe obstructive sleep apnea and a body mass index of 27 or higher. One trial, with 363 people, included those not using a CPAP machine. The other, with 349, included people who were using one. People with diabetes were excluded.

Everyone took orforglipron or a placebo pill for 52 weeks. The main measure was the apnea hypopnea index, AHI for short, the number of times an hour breathing stops or becomes very shallow during sleep.

The numbers

In the trial without CPAP, AHI fell by 17.8 events an hour on orforglipron and by 4.5 on placebo, a difference of 13.2 with a confidence interval of 8.7 to 17.7. In the trial with CPAP, it fell by 17.3 versus 5.3, a difference of 12.0, with a confidence interval of 6.9 to 17.1.

17.8

Fewer events an hour, on the pill

Trial without CPAP, after 52 weeks.

4.5

Fewer events an hour, on placebo

Same trial, same 52 weeks.

13.2

Difference

Confidence interval 8.7 to 17.7. The trial with CPAP found a difference of 12.0.

712 adults with moderate to severe obstructive sleep apnea and a BMI of 27 or more; people with diabetes excluded.

Body weight dropped by about 10 to 11 percent on the drug, against 1 to 2 percent on placebo, which is the most likely route for most of the improvement.

The cost was in the gut. Digestive side effects such as nausea were reported in 68.0 and 70.6 percent of people on orforglipron, against 37.4 and 36.6 percent on placebo.

How it compares

The reductions were smaller than those reported for injectable tirzepatide in its own sleep apnea trials. Reports also conflict on how people felt: a discussant at the AHA meeting said sleep related impairment did not improve significantly more than on placebo, while other coverage reported a greater improvement. So this is a meaningful drop in breathing events, not a cure.

a meaningful drop in breathing events, not a cure

Very few participants were Black, under 4 percent, which matters because sleep apnea affects many groups who were barely represented here. The trials were funded by Lilly.

Honest caveat

Both trials excluded people with diabetes, a large share of those who have sleep apnea. Most of the benefit likely comes from weight loss rather than any direct effect on breathing. Reports conflict on whether patient reported sleep impairment improved beyond placebo. These results do not mean the drug is approved for sleep apnea, and we did not find a regulatory decision on that use.

What this means for you

If you have sleep apnea and excess weight, these trials add to the evidence that losing weight, including with medication, can reduce the number of breathing pauses. It does not replace CPAP for someone who needs it, and the people in these trials who used CPAP kept using it.

If you are weighing a GLP-1 pill, the digestive side effects in these trials were common, and it is not settled whether people felt more rested than on placebo. Those are good questions to bring to a sleep specialist.

Primary sources

  1. JAMA, published online November 9, 2026: orforglipron for obstructive sleep apnea, two randomized clinical trials, DOI 10.1001/jama.2026.24080
  2. TCTMD, November 2026: ATTAIN-OSA results presented at AHA Scientific Sessions

Common questions

Is orforglipron approved for sleep apnea?

Orforglipron was approved by FDA for weight management in April 2026 under the brand name Foundayo, according to trade coverage, but we found no approval for sleep apnea as of November 19, 2026. Talk to a sleep specialist about current treatment options.

How much did it reduce breathing pauses?

By about 17 to 18 events an hour on the drug, against about 4 to 5 on placebo, so roughly 12 to 13 events an hour more than placebo after a year.

Can it replace a CPAP machine?

Not on this evidence. One of the two trials was in people who kept using CPAP, and the drug reduced breathing events without eliminating them.

Continue readingPeptidesA New Oral Pill Just Beat Oral Ozempic in a Head to Head TrialA 52 week phase 3 trial of 1,698 adults found Eli Lilly's oral pill orforglipron beat oral semaglutide on blood sugar control and weight loss, though with more GI side effects and a higher dropout rate.Read the storyRelated guideSleep ArchitectureHow sleep stages, breathing and timing fit together, and what actually improves them.Read the guide
OrforglipronGLP-1Sleep ApneaWeight LossClinical Trial

#Orforglipron#GLP1#SleepApnea#WeightLoss#ClinicalTrial

Stay Curious.

Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.